Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 373-378

  Gerullis, Holger ^a,b   Bergmann, Lothar ^c   Maute, Luise ^c   Ecke, Thorsten Holger ^d   Eimer, Christoph ^a   Bagner, Jens Willem ^a   Otto, Thomas ^a  

^a Lukaskrankenhaus GmbH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

Advanced renal cell carcinoma; Adverse events; Sequential use; Sunitinib; Temsirolimus

Indexed keywords

SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIVER TOXICITY; MAGNESIUM BLOOD LEVEL; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SYSTEMIC THERAPY; TASTE AVERSION; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 77955467608     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9220-1     Document Type: Article

References (18)

1. Jemal A, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57(1):43-66. doi:10.3322/canjclin.57.1.43.
2. Ljungberg B, et al. European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-10. doi:10.1016/j.eururo.2007.03.035. (Pubitemid 46634775)
3. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24. doi: 10.1056/NEJMoa065044. (Pubitemid 46089672)
4. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34. doi:10.1056/ NEJMoa060655.
5. Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40.
6. Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22): 2271-81. doi:10.1056/ NEJMoa066838. (Pubitemid 46849157)
7. Otto T, Eimer C, Gerullis H. Temsirolimus in renal cell carcinoma. Transplant Proc. 2008;40(10 Suppl):S36-9. doi:10.1016/ j.transproceed.2008.10. 006.
8. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol. 2009;63(6):1097-102. doi:10.1007/s00280- 008-0835-2.
9. Torisel [Package Insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2007.
10. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45(5):765-73. doi:10.1016/j.ejca.2008.12.010.
11. Rini BI et al. CALGB 90206. A Phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. ASCO Genitourinary Cancers Symposium 2008; Abstract 5033.
12. Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-56. doi:10.1016/S0140- 6736(08)61039-9.
13. Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-11. doi:10.1016/ S0140-6736(07)61904-7.
14. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009;103(5):572-7. doi:10.1111/j.1464- 410X.2008.08336.x.
15. Eichelberg C, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008;54(6):1373-8. doi:10.1016/j.eururo.2008.07.051.
16. Bhojani N, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917-30. doi:10.1016/j.eururo.2007.11.037.
17. Tamaskar I, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179(1):81-6. doi:10.1016/ j.juro.2007.08.127.
18. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):24-7.